Robert Perneczky1, Panagiotis Alexopoulos2. 1. Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London, UK; West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, UK; Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany. Electronic address: r.perneczky@imperial.ac.uk. 2. Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.
Abstract
OBJECTIVE: The objective of this study was to assess cerebrospinal fluid (CSF) β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) activity in relation to Alzheimer's disease (AD) and to correlate the enzyme activity with protein markers of APP metabolism and axonal degeneration. METHODS: BACE1 activity and protein concentrations were measured and analyzed in 342 participants of the Alzheimer's Disease Neuroimaging Initiative, including 99 normal control, 75 stable mild cognitive impairment (MCI), 87 progressive MCI, and 79 AD dementia cases. All statistical analyses were Bonferroni corrected for multiple comparisons. RESULTS: No significant differences between controls and any of the three patient groups were detected for BACE1 activity and soluble APPβ (sAPPβ) concentrations in CSF. Significant correlations with BACE1 activity were found for CSF APPβ and total tau in all four groups and for CSF phosphorylated tau181 in all groups but the progressive MCI group. There were no correlations for CSF amyloid β (Aβ)1-42 or for plasma Aβ1-42 and Aβ1-40. CONCLUSIONS: The consistent correlation between BACE1 activity and sAPPβ supports their role as biomarkers of target engagement in clinical trials on BACE1 inhibition.
OBJECTIVE: The objective of this study was to assess cerebrospinal fluid (CSF) β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) activity in relation to Alzheimer's disease (AD) and to correlate the enzyme activity with protein markers of APP metabolism and axonal degeneration. METHODS:BACE1 activity and protein concentrations were measured and analyzed in 342 participants of the Alzheimer's Disease Neuroimaging Initiative, including 99 normal control, 75 stable mild cognitive impairment (MCI), 87 progressive MCI, and 79 AD dementia cases. All statistical analyses were Bonferroni corrected for multiple comparisons. RESULTS: No significant differences between controls and any of the three patient groups were detected for BACE1 activity and soluble APPβ (sAPPβ) concentrations in CSF. Significant correlations with BACE1 activity were found for CSF APPβ and total tau in all four groups and for CSF phosphorylated tau181 in all groups but the progressive MCI group. There were no correlations for CSF amyloid β (Aβ)1-42 or for plasma Aβ1-42 and Aβ1-40. CONCLUSIONS: The consistent correlation between BACE1 activity and sAPPβ supports their role as biomarkers of target engagement in clinical trials on BACE1 inhibition.
Authors: Michael Ewers; Zhenyu Zhong; Katharina Bürger; Anders Wallin; Kaj Blennow; Stefan J Teipel; Yong Shen; Harald Hampel Journal: Brain Date: 2008-03-11 Impact factor: 13.501
Authors: R Perneczky; A Tsolakidou; A Arnold; J Diehl-Schmid; T Grimmer; H Förstl; A Kurz; P Alexopoulos Journal: Neurology Date: 2011-06-22 Impact factor: 9.910
Authors: Sandra D Mulder; Wiesje M van der Flier; Jan H Verheijen; Cees Mulder; Philip Scheltens; Marinus A Blankenstein; C Erik Hack; Robert Veerhuis Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: Henrik Zetterberg; Ulf Andreasson; Oskar Hansson; Guoxin Wu; Sethu Sankaranarayanan; Malin E Andersson; Peder Buchhave; Elisabet Londos; Robert M Umek; Lennart Minthon; Adam J Simon; Kaj Blennow Journal: Arch Neurol Date: 2008-08
Authors: Zhenyu Zhong; Michael Ewers; Stefan Teipel; Katharina Bürger; Anders Wallin; Kaj Blennow; Ping He; Carrie McAllister; Harald Hampel; Yong Shen Journal: Arch Gen Psychiatry Date: 2007-06
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Inmaculada Lopez-Font; Claudia P Boix; Henrik Zetterberg; Kaj Blennow; Javier Sáez-Valero Journal: Mol Neurobiol Date: 2019-07-09 Impact factor: 5.590
Authors: Ju-Hee Kang; Magdalena Korecka; Michal J Figurski; Jon B Toledo; Kaj Blennow; Henrik Zetterberg; Teresa Waligorska; Magdalena Brylska; Leona Fields; Nirali Shah; Holly Soares; Robert A Dean; Hugo Vanderstichele; Ronald C Petersen; Paul S Aisen; Andrew J Saykin; Michael W Weiner; John Q Trojanowski; Leslie M Shaw Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Samuel Pattillo Smith; Sahar Shahamatdar; Wei Cheng; Selena Zhang; Joseph Paik; Misa Graff; Christopher Haiman; T C Matise; Kari E North; Ulrike Peters; Eimear Kenny; Chris Gignoux; Genevieve Wojcik; Lorin Crawford; Sohini Ramachandran Journal: Am J Hum Genet Date: 2022-03-28 Impact factor: 11.043
Authors: Maarten Timmers; Soraia Barão; Bianca Van Broeck; Ina Tesseur; John Slemmon; Katja De Waepenaert; Jennifer Bogert; Leslie M Shaw; Sebastiaan Engelborghs; Dieder Moechars; Marc Mercken; Luc Van Nueten; Luc Tritsmans; Bart de Strooper; Johannes Rolf Streffer Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Harald Hampel; Robert Vassar; Bart De Strooper; John Hardy; Michael Willem; Neeraj Singh; John Zhou; Riqiang Yan; Eugeen Vanmechelen; Ann De Vos; Robert Nisticò; Massimo Corbo; Bruno Pietro Imbimbo; Johannes Streffer; Iryna Voytyuk; Maarten Timmers; Amir Abbas Tahami Monfared; Michael Irizarry; Bruce Albala; Akihiko Koyama; Naoto Watanabe; Teiji Kimura; Lisa Yarenis; Simone Lista; Lynn Kramer; Andrea Vergallo Journal: Biol Psychiatry Date: 2020-02-13 Impact factor: 13.382